Universal access to quality medicines: prioritisation of a-priori solutions
نویسندگان
چکیده
منابع مشابه
House of Improvement Model to Enhance Prioritisation of Solutions in Decision Making: a Case Study
The decision making on selection of improvement solutions was one of the obstacles hampering the success of process improvement. This paper presents the House of Improvement (HOI) model as a guideline to link decision criteria for the prioritisation of improvement solutions. Three phases in the HOI are applied to facilitate selection and to ensure that suitable and value-added solutions are cho...
متن کاملUniversal access to AIDS medicines: the brazilian experience1
This article focuses on the Brazilian policy for distribution of medicines to persons living with HIV/AIDS. It attempts to present readers with the social scenario in which this policy has been developed and implemented, and describes the history of how the epidemic has been dealt with in Brazil. Some historical references are mentioned in order to provide a better understanding of the principl...
متن کاملUniversal access to medicines: evidence from Rajasthan, India.
India has outlined its commitment to achieving universal health coverage and several states in India are rolling out strategies to support this aim. In 2011, Rajasthan implemented an ambitious universal access to medicines programme based on a centralized procurement and decentralized distribution model. In terms of the three dimensions of universal health coverage, the scheme has made signific...
متن کاملpharmaceutical strategic purchasing: a key to improve access to medicines
pharmaceuticals are often considered as the most significant cost driver of health care expenditures and at the same time have a major impact on patients’ curative processes and outcomes. other pieces of evidence emphasize that drugs are the input for the production of good health. they are considered as the most important and expensive element in the healthy supply chain and are more associate...
متن کاملRegulatory framework for access to safe, effective quality medicines.
Medicines of uncertain quality, safety and efficacy can be worse than no treatment at all. It is the responsibility of national medicines regulatory authorities to protect patients from harm. Yet, there are great disparities in regulatory capacity globally, preventing large populations from accessing the benefits of advances in the pharmaceutical field. This article describes the main regulator...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet Infectious Diseases
سال: 2012
ISSN: 1473-3099
DOI: 10.1016/s1473-3099(12)70259-1